Astrocytes derived from fetal neural progenitor cells as a novel source for therapeutic adenosine delivery

PurposeIntracerebral delivery of anti-epileptic compounds represents a novel strategy for the treatment of refractory epilepsy. Adenosine is a possible candidate for local delivery based on its proven anti-epileptic effects. Neural stem cells constitute an ideal cell source for intracerebral transplantation and long-term drug delivery. In order to develop a cell-based system for the long-term delivery of adenosine, we isolated neural progenitor cells from adenosine kinase deficient mice (Adk−/−) and compared their differentiation potential and adenosine release properties with corresponding wild-type cells.MethodsFetal neural progenitor cells were isolated from the brains of Adk−/− and C57BL/6 mice fetuses and expanded in vitro. Before and after neural differentiation, supernatants were collected and assayed for adenosine release using liquid chromatography–tandem mass spectrometry (LC–MS/MS).ResultsAdk−/− cells secreted significantly more adenosine compared to wild-type cells at any time point of differentiation. Undifferentiated Adk−/− cells secreted 137 ± 5 ng adenosine per 105 cells during 24 h in culture, compared to 11 ± 1 ng released from corresponding wild-type cells. Adenosine release was maintained after differentiation as differentiated Adk−/− cells continued to release significantly more adenosine per 24 h (47 ± 1 ng per 105 cells) compared to wild-type cells (3 ± 0.2 ng per 105 cells).ConclusionsFetal neural progenitor cells isolated from Adk−/− mice – but not those from C57BL/6 mice – release amounts of adenosine considered to be of therapeutic relevance.